Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
link https://doi.org/10.1101/2021.03.31.21254494account_box Bueno Ramírez, Susanaccount_box Abarca Villaseca, Katiaaccount_box González Adonis, Pablo Andrésaccount_box Gálvez Arriagada, Nicolás Marcelo Salvadoraccount_box Soto Ramírez, Jorge Andrésaccount_box Duarte Peñaloza, Luisa Fernandaaccount_box Schultz Lombardic, Bárbara M.account_box Pacheco, Gaspar A.account_box González Carreño, Liliana Andreaaccount_box Vázquez, Yaneisiaccount_box Ríos Raggio, Marianaaccount_box Melo González, Felipeaccount_box Rivera Pérez, Danielaaccount_box Iturriaga, Carolinaaccount_box Urzúa Acevedo, Marcela del Pilaraccount_box Domínguez De Landa, María Angélicaaccount_box Andrade Parra, Catalina Andreaaccount_box Berríos Rojas, Roslyeaccount_box Canedo Marroquín, Giseldaaccount_box Covián, Camila
Comparte este registro
The ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. The rapid development of safe and protective vaccines against this disease is a global priority. CoronaVac is a vaccine prototype based on inactivated SARS-CoV-2, which has shown promising safety and immunogenicity profiles in pre-clinical studies and phase 1/2 trials in China. To this day, four phase 3 clinical trials are ongoing with CoronaVac in Brazil, Indonesia, Turkey, and Chile. This article reports the safety and immunogenicity results obtained in a subgroup of participants aged 18 years and older enrolled in the phase 3 Clinical Trial held in Chile.
Registro Sencillo
Registro Completo
| Autor | Bueno Ramírez, Susan Abarca Villaseca, Katia González Adonis, Pablo Andrés Gálvez Arriagada, Nicolás Marcelo Salvador Soto Ramírez, Jorge Andrés Duarte Peñaloza, Luisa Fernanda Schultz Lombardic, Bárbara M. Pacheco, Gaspar A. González Carreño, Liliana Andrea Vázquez, Yaneisi Ríos Raggio, Mariana Melo González, Felipe Rivera Pérez, Daniela Iturriaga, Carolina Urzúa Acevedo, Marcela del Pilar Domínguez De Landa, María Angélica Andrade Parra, Catalina Andrea Berríos Rojas, Roslye Canedo Marroquín, Giselda Covián, Camila |
| Título | Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial |
| Revista | Clinical Infectious Diseases |
| ISSN | 1058-4838 |
| Página inicio | 1 |
| Página final | 32 |
| Fecha de publicación | 2021 |
| Resumen | The ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. The rapid development of safe and protective vaccines against this disease is a global priority. CoronaVac is a vaccine prototype based on inactivated SARS-CoV-2, which has shown promising safety and immunogenicity profiles in pre-clinical studies and phase 1/2 trials in China. To this day, four phase 3 clinical trials are ongoing with CoronaVac in Brazil, Indonesia, Turkey, and Chile. This article reports the safety and immunogenicity results obtained in a subgroup of participants aged 18 years and older enrolled in the phase 3 Clinical Trial held in Chile. |
| Derechos | acceso restringido |
| DOI | 10.1101/2021.03.31.21254494 |
| Enlace | |
| Temática | Medicina y salud |
| Tipo de documento | preprint |